Compass Therapeutics (CMPX) Reiterated at Buy by Stifel After ASCO Presentation

June 1, 2026 7:32 AM

Stifel analyst Stephen Willey reiterated a Buy rating and $6.00 price target on Compass Therapeutics (NASDAQ: CMPX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found